Literature DB >> 11830581

Identification and characterization of prolylcarboxypeptidase as an endothelial cell prekallikrein activator.

Zia Shariat-Madar1, Fakhri Mahdi, Alvin H Schmaier.   

Abstract

Our recent investigations have postulated a human umbilical vein endothelial cell (HUVEC)-associated prekallikrein activator (PKA). When prekallikrein (PK) assembles on high molecular weight kininogen on HUVEC, PK is activated to kallikrein. PKA was found in the 15,800 x g pellet of HUVEC lysates using an assay that measures PK activation only when bound to high molecular weight kininogen linked to microtiter plates. Sequential DEAE, wheat germ lectin affinity, and hydroxyapatite chromatography resulted in four protein bands on SDS-PAGE. One protein in the 73-kDa band was identified by amino acid sequencing as prolylcarboxypeptidase (PRCP). On gel filtration, PKA activity was a single homogenous peak identical in migration to the 73-kDa immunoblot of PRCP. Anti-PRCP inhibits PKA activity and PK activation on HUVEC. Purified PKA was blocked by diisopropyl fluorophosphate (1 mm), phenylmethylsulfonyl fluoride (3 mm), leupeptin (100 microm), antipain (IC(50) = 2 microm), HgCl(2) (IC(50) = 500 microm), Z-Pro-Pro-aldehyde-dimethyl acetate (IC(50) = 1 microm), and corn trypsin inhibitor (IC(50) = 40 nm). PKA did not correct the coagulant defect in factor XII deficient plasma, was purified from HUVEC cultured in factor XII-deficient serum, was not detected by antibody to factor XII, did not activate FXI, and was not inhibited by a neutralizing antibody to FXII. Angiotensin II (IC(50) = 2 microm) or bradykinin (IC(50) = 100 microm), but not angiotensin II-(1-7) or bradykinin(1-5), and the prolyl oligopeptidase inhibitor Fmoc-Ala-Pyr-CN (IC(50) = 50 nm) also blocked purified PKA activation of PK. The K(m) of PK activation by PRCP is 6.7 nm. PRCP antigen is present on the membrane of fixed but not permeabilized HUVEC. PRCP appears to be a HUVEC-associated PK activator.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11830581     DOI: 10.1074/jbc.M106101200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  70 in total

Review 1.  The plasma kallikrein-kinin system counterbalances the renin-angiotensin system.

Authors:  Alvin H Schmaier
Journal:  J Clin Invest       Date:  2002-04       Impact factor: 14.808

2.  Influence of a novel inhibitor (UM8190) of prolylcarboxypeptidase (PRCP) on appetite and thrombosis.

Authors:  F M Rabey; R S V S Gadepalli; S Diano; Q Cheng; T Tabrizian; D Gailani; J M Rimoldi; Z Shariat-Madar
Journal:  Curr Med Chem       Date:  2012       Impact factor: 4.530

Review 3.  Contribution of angiotensin-(1-7) to cardiovascular physiology and pathology.

Authors:  Carlos M Ferrario
Journal:  Curr Hypertens Rep       Date:  2003-04       Impact factor: 5.369

4.  A kallikrein-targeting RNA aptamer inhibits the intrinsic pathway of coagulation and reduces bradykinin release.

Authors:  K-A Steen Burrell; J Layzer; B A Sullenger
Journal:  J Thromb Haemost       Date:  2017-08-02       Impact factor: 5.824

5.  The hereditary angioedema syndromes.

Authors:  Alvin H Schmaier
Journal:  J Clin Invest       Date:  2018-12-10       Impact factor: 14.808

6.  Neutrophils contain prolyl endopeptidase and generate the chemotactic peptide, PGP, from collagen.

Authors:  Philip J O'Reilly; Matthew T Hardison; Patricia L Jackson; Xin Xu; Robert J Snelgrove; Amit Gaggar; F Shawn Galin; J Edwin Blalock
Journal:  J Neuroimmunol       Date:  2009-10-28       Impact factor: 3.478

Review 7.  Complement, Kinins, and Hereditary Angioedema: Mechanisms of Plasma Instability when C1 Inhibitor is Absent.

Authors:  Allen P Kaplan; Kusumam Joseph
Journal:  Clin Rev Allergy Immunol       Date:  2016-10       Impact factor: 8.667

8.  Physiologic activities of the contact activation system.

Authors:  Alvin H Schmaier
Journal:  Thromb Res       Date:  2014-05       Impact factor: 3.944

9.  A monoclonal antibody to high-molecular weight kininogen is therapeutic in a rodent model of reactive arthritis.

Authors:  Ricardo G Espinola; Audrey Uknis; Irma M Sainz; Irma Isordia-Salas; Robin Pixley; Raul DeLa Cadena; Walter Long; Alexis Agelan; John Gaughan; Albert Adam; Robert W Colman
Journal:  Am J Pathol       Date:  2004-09       Impact factor: 4.307

10.  A comparison of the effects of factor XII deficiency and prekallikrein deficiency on thrombus formation.

Authors:  Yasin Kokoye; Ivan Ivanov; Qiufang Cheng; Anton Matafonov; S Kent Dickeson; Shauna Mason; Daniel J Sexton; Thomas Renné; Keith McCrae; Edward P Feener; David Gailani
Journal:  Thromb Res       Date:  2016-02-18       Impact factor: 3.944

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.